The latest news from RHEINCELL
RheinCell’s success story
Read about the growth path of RheinCell and what the future might hold in the IHK/Chamber of Commerce and Industry-Magazin
RheinCell Therapeutics to be acquired by Catalent, Accelerating the Industrialization of iPSC-based Therapies
Catalent Pharma Solutions, the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics, cell and gene therapy and consumer health products, has agreed to acquire RHEINCELL Therapeutics.
RHEINCELL IS AT ADVANCED THERAPIES 2021 VIRTUAL
Continuously seeking new partnerships and innovative collaborations, Thomas Marx is attending this year's virtual session of Advanced Therapies Congress & Expo. Cutting-edge talks and insightful discussions packed into 3 high-power days will keep Thomas busy. Make sure to join him.
RHEINCELL WILL BE AT ISSCR 2021 VIRTUAL
Our colleagues Thomas Marx and Dr. Katja Aschermann will be attending this year's virtual ISSCR meeting. As always, the program is an outstanding list of thought leaders, innovation drivers, and world-class researchers. We hope to see you there.
RheinCell teams up with RegMedNet to shine a spotlight on iPSCs
RegMedNet has just announced a new In Focus feature taking a close look at how induced pluripotent stem cells can catalyze the advancement of novel cell therapies. Prepared in collaboration with RheinCell experts, the feature explores biological, clinical and commercial characteristics of iPSCs as ideal starting materials.
A NEW PUBLICATION ON THE POTENTIAL OF IPSCS
The April issue of the European Biopharmaceutical Review includes a thought leadership article authored by Thomas Marx and Boris Greber. In it, they explore the potential of induced pluripotent stem cells as meticulously defined starting materials for advanced therapies.
THOMAS MARX AND BORIS GREBER DISCUSS THE POTENTIAL OF IPSCs
In an informative interview with Michael Adeniya, Portfolio Director of Phacilitate Exchange, Boris Greber and Thomas Marx answer questions about the position of induced pluripotent stem cells in today’s advanced therapies market and the transformative power latent in their clinical application.
Now you can stay up to date with rheincell news
The advanced therapies market moves quickly with news, updates and breakthroughs every day. As a dynamic and engaged company, we continue to achieve milestones, bring novel ideas, products and services to customers, and expand our partnerships. Follow these developments and activities here on this news page.
Rheincell will be at advanced therapies connect 2021
What: A virtual event with strong content agenda where an international network of suppliers, developers and providers of advanced therapies meet to forge collaborations and advance commercial cell-based therapies.
When: January 26 – 27, 2021
RheinCell Therapeutics achieves milestone GMP certification
We are proud to announce that Rheincell has GMP certification and Manufacturing Authorization to supply clinical-grade iPSCs and thus, make a meaningful contribution to advancing cell therapies.
A special thank you goes out to our team who worked tirelessly to achieve this milestone.